Dysregulated glycosylation is associated with TGF-β signaling and TGF-β-induced EMT in various cancers (46) by affecting the secretion, bioavailability of TGF-β (47), TβRII localization in cells, and interaction with TGF-β (48). Here, TGFB1 is linked to cancer.